The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: An international prospective cohort study

Gynecologic Oncology

Volumn 130, Issue 1, 2013, Pages 127-131

  Segev, Yakir ^a,f   Iqbal, Javaid ^a   Lubinski, Jan ^b   Gronwald, Jacek ^b   Lynch, Henry T ^c   Moller, Pal ^d   Ghadirian, Parviz ^e   Rosen, Barry ^f   Tung, Nadine ^g   Kim Sing, Charmaine ^h   Foulkes, William D ⁱ   Neuhausen, Susan L ^j   Senter, Leigha ^k   Singer, Christian F ^l   Karlan, Beth ^m   Ping, Sun ^a   Narod, Steven A ^a  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

^b POMERANIAN MEDICAL UNIVERSITY   (Poland)

^c CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^h BRITISH COLUMBIA CANCER AGENCY   (Canada)

ⁱ MCGILL UNIVERSITY   (Canada)

^j City of Hope ^*  (United States)

^k THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^l UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^m CEDARS SINAI MEDICAL CENTER   (United States)

more..

Author keywords

BRCA1; BRCA2; Endometrial cancer

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CHEMOPROPHYLAXIS; COHORT ANALYSIS; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; GENE MUTATION; GROUPS BY AGE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL HISTORY; PRIORITY JOURNAL; PROSPECTIVE STUDY; STANDARDIZED INCIDENCE RATIO;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; COHORT STUDIES; ENDOMETRIAL NEOPLASMS; EUROPE; FEMALE; GENES, BRCA1; GENES, BRCA2; GERM-LINE MUTATION; HUMANS; INCIDENCE; MIDDLE AGED; NORTH AMERICA; OVARIECTOMY; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; TAMOXIFEN;

EID: 84879106640     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.03.027     Document Type: Article

References (21)

1. J. Ferlay, F. Bray, D. Forman, C. Mathers, and D.M. Parkin Cancer incidence and mortality worldwide: IARC CancerBase No. 10 [Internet] 2010 GLOBOCAN 2008, International Agency for Research on Cancer Lyon, France (Available from: http://globocan.iarc.fr)
2. M.E. Beiner, A. Finch, B. Rosen, J. Lubinski, P. Moller, and P. Ghadirian The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study Gynecol Oncol 104 2007 7 10
3. D. Thompson, and D.F. Easton Breast Cancer Linkage Consortium. Cancer incidence in BRCA1 mutation carriers J Natl Cancer Inst 94 2002 1358 1365
4. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium J Natl Cancer Inst 91 1999 1310 1316
5. R. Moslehi, W. Chu, B. Karlan, D. Fishman, H. Risch, and A. Fields BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer Am J Hum Genet 66 2000 1259 1272
6. D.A. Levine, O. Lin, R.R. Barakat, M.E. Robson, D. McDermott, and L. Cohen Risk of endometrial carcinoma associated with BRCA mutation Gynecol Oncol 80 2001 395 398
7. J. Iqbal, O.M. Ginsburg, T.D. Wijeratne, A. Howell, G. Evans, and I. Sestak Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: a systematic review Cancer Treat Rev 38 2012 318 328
8. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) C. Davies, J. Godwin, R. Gray, M. Clarke, and D. Cutter Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials Lancet 378 2011 771 784
9. D.L. Duffy, Y.C. Antill, C.J. Stewart, J.P. Young, kConFab, and A.B. Spurdle Report of endometrial cancer in Australian BRCA1 and BRCA2 mutation-positive families Twin Res Hum Genet 14 2011 111 118
10. L. Bergman, M.L. Beelen, M.P. Gallee, H. Hollema, J. Benraadt, and F.E. van Leeuwen Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen Lancet 356 2000 881 887
11. S.A. Narod, T. Pal, T. Graham, M. Mitchell, and A. Fyles Tamoxifen and risk of endometrial cancer Lancet 357 2001 65 66
12. O. Lavie, O. Barnett-Griness, S.A. Narod, and G. Rennert The risk of developing uterine sarcoma after tamoxifen use Int J Gynecol Cancer 18 2008 352 356
13. O. Lavie, A. Ben-Arie, Y. Segev, J. Faro, F. Barak, and N. Haya BRCA germline mutations in women with uterine serous carcinoma-still a debate Int J Gynecol Cancer 20 2010 1531 1534
14. T. Biron-Shental, L. Drucker, M. Altaras, J. Bernheim, and A. Fishman High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma Eur J Surg Oncol 32 2006 1097 1100
15. R. Goshen, W. Chu, L. Elit, T. Pal, J. Hakimi, and I. Ackerman Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome? Gynecol Oncol 79 2000 477 481
16. K.P. Pennington, T. Walsh, M. Lee, C. Pennil, A.P. Novetsky, and K.J. Agnew BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma Cancer 119 2013 332 338
17. C. La Vecchia, L.A. Brinton, and A. McTiernan Menopause, hormone replacement therapy and cancer Maturitas 39 2001 97 115
18. V. Beral, D. Bull, and G. Reeves Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study Lancet 365 2005 1543 1551
19. L.F. Voigt, N.S. Weiss, J. Chu, J.R. Daling, B. McKnight, and G. van Belle Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer Lancet 338 1991 274 277
20. A. Eisen, J. Lubinski, J. Gronwald, P. Moller, H.T. Lynch, and J. Klijn Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers J Natl Cancer Inst 100 2008 1361 1367
21. J.M. Lancaster, C.B. Powell, N.D. Kauff, I. Cass, L.M. Chen, and K.H. Lu Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions Gynecol Oncol 107 2007 159 162